Home>Topics>Companies>Abbott Laboratories

Abbott Laboratories ABT

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. New Morningstar Analyst Report for Abbott Laboratories

      Stock Reports

      Tue, 22 Jul 2014

      Clinical data on drug-eluting stents and alternative therapies have put a crimp in percutaneous coronary procedures, as medical therapy and coronary bypass have gained favor.Abbott faces an uphill battle in the diagnostics arena where it must go head-to-head against market leader Roche, along with

    2. Why Abbott's Stake In Mylan Will Be Value-Creative

      Headlines

      Mon, 21 Jul 2014

      By Valuentum : Abbott ( NYSE : ABT ) has a track record that is unrivaled. The firm is more than 125 years old and remains aligned with favorable long-term healthcare

    3. Abbott Laboratories Declared Its 362nd Quarterly Dividend, But Earnings Were Mediocre

      Headlines

      Thu, 17 Jul 2014

      By Abba's Aces: The last time I wrote about Abbott Laboratories ( NYSE : ABT ) I stated: "Like I said, I will only be buying a small batch this time around, only for the dividend. I think the entire

    4. Abbott Laboratories' (ABT) CEO, Miles White on Q2 2014 Results - Earnings Call Transcript

      Headlines

      Wed, 16 Jul 2014

      Abbott Laboratories ( NYSE : ABT ) Q2 2014 Earnings Conference Call July 16, 2014 9:00 am ET Executives Miles White – Chairman, Chief Executive Officer Thomas Freyman

    5. Abbott Labs Delivers Slightly Better-Than-Expected 2Q

      Commentary

      Wed, 16 Jul 2014

      Abbott posted mixed second-quarter results that on balance slightly exceeded our expectations, but not enough to move the needle on our valuation. However, we do plan to modestly bump up our fair value estimate after incorporating the acquisitions of CFR and Veropharm, along with the divestment of

    6. More on Abbott Q2 results. Guidance raised.

      Headlines

      Wed, 16 Jul 2014

      Abbott Laboratories ( ABT +0.2% ) Q2 results: Total Revenues: $5,551M (+1.9%); International Revs: $3,990M (+2.7%); U.S. Revs

    7. BRIEF-Abbott CEO says growth for nutritional products, pharmaceuticals "getting back on track"

      Headlines

      Wed, 16 Jul 2014

      July 16 (Reuters) - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals

    8. Abbott beats second quarter profit forecast

      Headlines

      Wed, 16 Jul 2014

      July 16 (Reuters) - Abbott Laboratories Inc on Wednesday reported better than expected second quarter earnings, helped by strong sales of its medical diagnostics products.

    9. Sanofi held talks with Abbott, Mylan on mature drugs -document

      Headlines

      Wed, 16 Jul 2014

      PARIS, July 16 (Reuters) - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs,...

    10. Abbott Laboratories beats by $0.03, beats on revenue

      Headlines

      Wed, 16 Jul 2014

      Abbott Laboratories ( NYSE : ABT ): Q2 EPS of $0.54 beats by $0.03 . Revenue of $5.55B (+1.8% Y/Y) beats by $30M . Press Release Post your comment!

    « Prev12345Next »
    Content Partners